On Jan. 9, 2026, Novartis announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company’s $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling US manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live.

The new 35,000-square-foot facility in Winter Park, Florida, will come online by 2029 and will strengthen Novartis’ specialized supply chain and manufacturing capabilities across its network of RLT production facilities. The new facility will optimize the delivery of RLT medicines to patients in the southeast US and help maintain the company’s steady rate of >99% of doses administered on the planned day as the potential for this promising treatment modality continues to expand.

RLT is a type of precision treatment that pairs a tumor-targeting molecule (ligand) with a therapeutic radioisotope, allowing radiation to be delivered directly to the tumor while minimizing harm to surrounding healthy tissue. Each RLT dose is individually prepared, and its delivery is highly time sensitive. Proximity to treatment facilities and transportation hubs is critical to ensure patients receive their therapy promptly and at the right location. RLT has the potential to transform oncology treatment and bring new options to people living with cancer.